Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mark J RatainPeter J O'Dwyer

Abstract

This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma. Patients initially received oral sorafenib 400 mg twice daily during the initial run-in period. After 12 weeks, patients with changes in bidimensional tumor measurements that were less than 25% from baseline were randomly assigned to sorafenib or placebo for an additional 12 weeks; patients with > or = 25% tumor shrinkage continued open-label sorafenib; patients with > or = 25% tumor growth discontinued treatment. The primary end point was the percentage of randomly assigned patients remaining progression free at 24 weeks after the initiation of sorafenib. Of 202 patients treated during the run-in period, 73 patients had tumor shrinkage of > or = 25%. Sixty-five patients with stable disease at 12 weeks were randomly assigned to sorafenib (n = 32) or placebo (n = 33). At 24 weeks, 50% of the sorafenib-treated patients were progression free versus 18% of the placebo-treated patients (P = .0077). Median progression-free survival (PFS) from randomization was significantly longer with sorafenib (24 weeks) t...Continue Reading

References

Oct 1, 1975·Journal of Clinical Pharmacology·W Amery, J Dony
Jan 1, 1981·Cancer·A B MillerA Winkler
Sep 1, 1993·Journal of Clinical Epidemiology·J A KopecJ M Esdaile
Nov 1, 1996·Epilepsy Research·C ChironL Gram
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Feb 23, 2002·The American Journal of Surgical Pathology·Mahul B AminMani Menon
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Oct 9, 2002·Current Pharmaceutical Design·Scott Wilhelm, Du-Shieng Chien
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary L RosnerMark J Ratain
Feb 5, 2003·Onkologie·R A HilgerD Strumberg
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Oct 13, 2004·Arthritis and Rheumatism·Jolanda CibereJohn M Esdaile
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J Ratain, S Gail Eckhardt
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerMark J Ratain
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey W ClarkHeinz-Josef Lenz
Sep 11, 2007·Science·N L Farr

❮ Previous
Next ❯

Citations

Apr 20, 2006·Der Urologe. Ausg. A·M AutenriethJ E Gschwend
Jul 1, 2008·Der Urologe. Ausg. A·A S Merseburger, M A Kuczyk
Dec 1, 2006·Cancer Chemotherapy and Pharmacology·Hassane IzzedineGilbert Deray
Apr 4, 2009·Cancer Chemotherapy and Pharmacology·David J Reeves, Chin Y Liu
Aug 13, 2009·Cancer Chemotherapy and Pharmacology·Judith Meza-JuncoMichael B Sawyer
Oct 14, 2010·Cancer Chemotherapy and Pharmacology·Apostolia M TsimberidouRazelle Kurzrock
Feb 10, 2011·Cancer Chemotherapy and Pharmacology·Alejandro D RicartScot C Remick
Nov 28, 2012·Cancer Chemotherapy and Pharmacology·Wei-Xiang QiZan Shen
Mar 7, 2007·World Journal of Urology·Christoph W M ReuterArnold Ganser
Aug 28, 2007·World Journal of Urology·Rosamonde E BanksPeter J Selby
Feb 13, 2008·World Journal of Urology·Jean-Jacques PatardStéphane Culine
Apr 9, 2008·World Journal of Urology·Vincenzo FicarraWalter Artibani
Nov 13, 2008·World Journal of Urology·Christopher P Evans
Jan 29, 2008·Cancer Metastasis Reviews·K N SyrigosMuhammad Wasif Saif
Aug 29, 2006·Investigational New Drugs·Ulka N VaishampayanLawrence E Flaherty
Apr 27, 2007·Investigational New Drugs·Pavel KrejciWilliam R Wilcox
Oct 22, 2008·Investigational New Drugs·Nicolas Penel, Antoine Adenis
Aug 29, 2013·Investigational New Drugs·Prasanth GanesanApostolia M Tsimberidou
Dec 17, 2011·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Fei LiuQianyuan Zhuang
Jul 20, 2007·Current Treatment Options in Oncology·Maryam B Lustberg, Martin J Edelman
Feb 10, 2007·Current Oncology Reports·Nancy L Lewis
Sep 4, 2008·Current Oncology Reports·Naomi B Haas, Robert Uzzo
Feb 15, 2011·Current Oncology Reports·Pankaj Bhargava, Murray O Robinson
Mar 28, 2008·Current Urology Reports·Rishi Sawhney, Fairooz Kabbinavar
Nov 1, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Begoña Mellado, Pere Gascón
Nov 3, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J BellmuntJ Albanell
Jun 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Hernán Cortés-Funes
Jul 10, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joaquim BellmuntLeyrer Urruticoechea
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Carolina MurielÁngel J Lacave
Dec 25, 2007·Lancet·Robert J Motzer, Ethan Basch
Aug 28, 2009·Expert Reviews in Molecular Medicine·Evon PoonMargaret Ashcroft
Jan 25, 2012·Journal of Proteome Research·Vibeke Hervik BullBernd Thiede
Aug 1, 2009·Journal of Human Genetics·Wei ZhangMark J Ratain
Apr 15, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Markus BrunnerBoban M Erovic
Apr 6, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Steven I Sherman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Bernard EscudierTARGET Study Group
The New England Journal of Medicine
R J MotzerRobert A Figlin
JAMA : the Journal of the American Medical Association
R J MotzerM Dror Michaelson
© 2022 Meta ULC. All rights reserved